secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-07-10T21:29:46+00:00
Accession:  0001193125-26-301052
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma raises $50M in private placement led by Cormorant and Columbia Threadneedle
--------------------------------------------------------------------------------

- Gross proceeds of $50M from sale of 1,418,071 shares at $33.21/share and pre-funded warrants for 87,500 shares at $33.209.
- Private placement led by Cormorant Asset Management and Columbia Threadneedle Investments; expected to close July 13, 2026.
- Net proceeds to fund clinical development and general corporate purposes; CEO cites upcoming Phase 2 CSU data from Ascendant Health expected by Q3 2026.
- Board granted 1,064,492 RSUs to employees and executives, including 655,074 RSUs to CEO Shao-Lee Lin, with time and performance-based vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526301052/0001193125-26-301052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526301052/d123955d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-301052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer